BioNTech SE Sponsored ADR $BNTX Shares Sold by Carmignac Gestion

Carmignac Gestion reduced its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 21.8% during the first quarter, Holdings Channel.com reports. The fund owned 112,711 shares of the company’s stock after selling 31,376 shares during the quarter. Carmignac Gestion’s holdings in BioNTech were worth $9,956,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. Amundi grew its stake in shares of BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after purchasing an additional 25,506 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of BioNTech by 15.5% in the 1st quarter. Royal Bank of Canada now owns 46,991 shares of the company’s stock worth $4,177,000 after purchasing an additional 6,308 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of BioNTech in the 1st quarter worth approximately $499,000. Finally, Sei Investments Co. acquired a new stake in BioNTech during the first quarter valued at approximately $220,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Price Performance

BNTX stock opened at $90.58 on Monday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The firm has a 50-day moving average of $91.48 and a two-hundred day moving average of $97.40. The firm has a market capitalization of $22.91 billion, a PE ratio of -15.40 and a beta of 1.27. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, May 4th. The company reported ($2.26) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.26. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business had revenue of $136.71 million for the quarter, compared to the consensus estimate of $207.42 million. During the same period last year, the firm posted ($1.73) earnings per share. The firm’s quarterly revenue was down 35.4% compared to the same quarter last year. On average, analysts forecast that BioNTech SE Sponsored ADR will post -5.79 earnings per share for the current year.

BioNTech declared that its board has authorized a stock repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 4.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Canaccord Genuity Group cut their price objective on BioNTech from $171.00 to $158.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. HC Wainwright reissued a “buy” rating and set a $130.00 price objective on shares of BioNTech in a research note on Monday, April 27th. Finally, Wells Fargo & Company decreased their target price on BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.12.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.